Challenges of guarantee-time bias

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2963-2969

  Giobbie Hurder, Anita ^a   Gelber, Richard D ^a,b,c   Regan, Meredith M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

AMENORRHEA; ANALYTIC METHOD; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONDITIONAL LANDMARK ANALYSIS; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVENT FREE SURVIVAL; FOLLOW UP; GENE MUTATION; GUARANTEE TIME BIAS; HUMAN; IMMORTAL TIME BIAS; INVERSE PROBABILITY WEIGHTED MODEL; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PATHOLOGIC COMPLETE RESPONSE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELECTION BIAS; STATISTICAL BIAS; SURVIVOR BIAS; SURVIVOR TREATMENT SELECTION BIAS; TREATMENT DURATION; TREATMENT RESPONSE; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; FEMALE; GENETICS; METHODOLOGY; MUTATION; ONCOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SURVIVAL;

AMENORRHEA; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MEDICAL ONCOLOGY; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 84891385168     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.5283     Document Type: Article

References (26)

1. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
2. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26:3913-3915, 2008
3. Gail MH: Does cardiac transplantation prolong life? A reassessment. Ann Intern Med 76:815-817, 1972
4. Sylvestre MP, Huszti E, Hanley JA: Do Oscar winners live longer than less successful peers? A reanalysis of the evidence. Ann Intern Med 145:361-363, 2006
5. Suissa S: Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492-499, 2008
6. Swain SM, Jeong JH, Geyer CE Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065, 2010
7. Swain SM, Jeong JH, Wolmark N: Amenorrhea from breast cancer therapy: Not a matter of dose. N Engl J Med 363:2268-2270, 2010
8. Colleoni M, Gelber S, Goldhirsch A, et al: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24:1332-1341, 2006
9. Shepherd LE, Chapman JA, Ali SM, et al: Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA 27. J Clin Oncol 30:7s, 2012 (suppl; abstr 501)
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for industry: Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer-Use as an endpoint to support accelerated approval. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ default.htm
11. Von Minckwitz, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012
12. Souhami L, Bae K, Pilepich M, et al: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31. J Clin Oncol 27:2137-2143, 2009
13. Tangen CM, Goldman BH, Swanson GP, et al: Biased hormonal therapy duration analysis makes results uninterpretable. J Clin Oncol 27: E203, 2009
14. Montomoli J, Hamilton-Dutoit SJ, Frøslev T, et al: Retrospective analysis of KRAS status in metastatic colorectal cancer patients: A single center feasibility study. Clin Exp Gastroenterol 5:167-171, 2012
15. Dafni U: Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 4:363-371, 2011
16. Snapinn S, Jiang Q, Iglewicz B: Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat 59:301-307, 2005
17. Simon R, Makuch RW: A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med 3:35-44, 1984
18. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model-Statistics for Biology and Health. New York, NY, Springer, 2000
19. Bouwhuis MG, Suciu S, Testori A, et al: Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: Prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 28:2460-2466, 2010
20. Schneider BP, Zhao F, Wang M, et al: Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 30: 3051-3057, 2012
21. Horvitz DG, Thompson DJ: A generalization of sampling without replacement from a finite universe. J Am Stat Assoc 260:663-685, 1952
22. Murphy SA, van der Laan MJ, Robins J: Marginal means models for dynamic regimes. J Am Stat Assoc 96:1410-1423, 2001
23. Hernán MA, Brumback B, Robins JM: Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc 96:440-448, 2001
24. Curtis LH, Hammill BG, Eisenstein EL, et al: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 45:S103-S107, 2007
25. Tricoci P Lokhnygina Y Berdan LG et al: Time to coronary angiography and outcomes among patients with high-risk non ST-segment evaluation acute coronary syndromes: Results from the SYNERGY trial. Circulation 116: 2669-2677, 2007
26. Van der Wal WM, Geskus RB: IPW: An R package for inverse probability weighting. J Stat Softw 43:1-23, 2011